Clinical Trials Logo

Endometrioid Carcinoma clinical trials

View clinical trials related to Endometrioid Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT05080556 Recruiting - Ovarian Cancer Clinical Trials

Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer

ACTOv
Start date: May 24, 2023
Phase: Phase 2
Study type: Interventional

ACTOv will compare standard 3-weekly carboplatin (AUC5), to carboplatin delivered according to an AT regimen. The AT regimen will modify carboplatin dose according to changes in the clinical-standard serum biomarker CA125 as a proxy measure of total tumour burden and an individual patient's response to the most recent chemotherapy treatment. AT could prolong sensitivity to carboplatin and extend tumour control, while simultaneously reducing chemotherapy dose and drug-induced toxicity. Carboplatin is a low cost and low toxicity drug that has an enduring and central role in ovarian cancer treatment.

NCT ID: NCT03875820 Active, not recruiting - Pancreatic Cancer Clinical Trials

Phase I Trial of Defactinib and VS-6766.

FRAME
Start date: December 12, 2017
Phase: Phase 1
Study type: Interventional

This is a multi-centre, investigator-initiated, dose escalation, Phase I trial of the combination of the FAK inhibitor, Defactinib (VS-6063), and the dual RAF/MEK inhibitor, VS-6766 (RO5126766) in patients with advanced solid tumours. VS-6766 (RO5126766) is the same compound as CH5126766. There are two parts to this study, the dose escalation phase and the dose expansion phase. In the dose escalation phase, cohorts of 3 to 6 patients will be enrolled to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D). This will be followed by a dose expansion phase to further characterise the safety and tolerability and to assess the pharmacodynamic activity of the combination.

NCT ID: NCT01732432 Withdrawn - Endometriosis Clinical Trials

Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC)

EAOC
Start date: October 2012
Phase: N/A
Study type: Observational

The purpose of this study is to determine whether a relationship exists between a previously established diagnosis of endometriosis and the consecutive risk of developing a clear cell or endometrioid ovarian carcinoma. All histopathological records since 1980 with these diagnoses (endometriosis, clear cell and endometrioid ovarian carcinoma) will be reviewed. Cancer registry data will be assessed to investigate differences in survival of women with endometriosis-associated ovarian carcinomas and those ovarian carcinoma patients without previous diagnosis of endometriosis.